Combination of melatonin and certain drugs for treatment of diabetic nephropathy in streptozotocin-induced diabetes in rats

被引：11

作者：

Motawi T.K. ^{[1
]}

Ahmed S.A. ^{[2
]}

Hamed M.A. ^{[2
]}

El-Maraghy S.A. ^{[1
]}

Aziz W.M. ^{[2
]}

机构：

[1] Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo

[2] Therapeutic Chemistry Department, National Research Centre (ID: 60014618), 33 El-Bohouth St., Dokki, Cairo

来源：

Diabetology International | 2016年 / 7卷 / 4期

关键词：

Diabetic nephropathy; LSP; Melatonin; Rowatinex;

D O I：

10.1007/s13340-016-0268-9

中图分类号：

学科分类号：

摘要：

Diabetic nephropathy is a major complication of diabetes and a leading cause of end-stage renal failure in many developed countries. The study aimed to evaluate the efficiency of certain drugs and melatonin in the treatment of nephropathy secondary to diabetes. Diabetes was induced in rats by a single intraperitoneal injection of streptozotocin (50 mg/kg body weight). Three days after induction of diabetes (460–500 mg/dl), rats were treated daily for 60 days with Rowatinex, melatonin, Rowatinex + melatonin, Amosar (Losartan Potassium) (LSP) and LSP + melatonin. The evaluations were made by measuring blood urea nitrogen (BUN), serum uric acid, serum creatinine, urine creatinine, creatinine clearance, nitric oxide, malondialdehyde, superoxide dismutase, glutathione, total antioxidant capacity, kidney injury molecule-1, heat shock protein-70, caspase-3, transforming growth factor β1, and DNA degradation by comet assay and total protein contents. The histopathological picture of the kidneys and pancreases was confirmed in our results. Diabetic rats showed drastic changes in all the measured parameters. Treatment with melatonin and the selected drugs revealed amelioration levels with variable degrees. In conclusion, the combination of LSP and melatonin had the most potent effect on treating the deleterious action of diabetes on rat kidney. © 2016, The Japan Diabetes Society.

引用

页码：413 / 424

页数：11

共 62 条

[1]

Schena F.P., Gesualdo L., Pathogenetic mechanisms of diabetic nephropathy, J Am Soc Nephrol, 16, pp. S30-S33, (2005)

[2]

Yoh K., Hirayama A., Ishizaki K., Et al., Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice, Genes Cells, 13, pp. 1159-1170, (2008)

[3]

Lewis E.J., Xu X., Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin, Diab Care, 31, pp. S202-S207, (2008)

[4]

Schaeffer V., Hansen K.M., Morris D.R., Abrass C.K., Reductions in laminin beta2 mRNA translation are responsible for impaired IGFBP-5-mediated mesangial cell migration in the presence of high glucose, Am J Physiol Renal Physiol, 298, pp. F314-F322, (2010)

[5]

Yozai K., Shikata K., Sasaki M., Et al., Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions, J Am Soc Nephrol, 16, pp. 3326-3338, (2005)

[6]

Seon Y.D., Lee T.H., Lee M.C., Changes of glomerular basement membrane components in Vacor-induced diabetic nephropathy, Korean J Intern Med, 14, pp. 77-84, (1999)

[7]

Micah L., Thorp D.O., Diabetic nephropathy: common questions, Am Fam Physician, 72, pp. 96-99, (2005)

[8]

Paredes S.D., Korkmaz A., Manchester L.C., Tan D.X., Reiter R.J., Phytomelatonin: a review, J Exp Botany, 60, pp. 57-69, (2009)

[9]

Boutin J.A., Audinot V., Ferry G., Delagrange P., Molecular tools to study melatonin pathways and actions, Trends Pharmacol Sci, 26, pp. 412-419, (2005)

[10]

Hardeland R., Pandi-Perumal S.R., Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug, Nut Metab, 2, (2005)

← 1 2 3 4 5 6 7 →